10 January 2023 - - US-based bioscience company ChromaDex Corp. (NASDAQ: CDXC) has appointed Brianna Gerber to the role of chief financial officer, effective January 1, 2023, the company said.

Gerber served as senior vice president, Finance / Interim chief financial officer of ChromaDex since August 11, 2022, and prior to that was the vice president of Finance and Investor Relations of ChromaDex since September 17, 2018.

Gerber has over 20 years of diverse experience in investment management, investor relations and finance, including strategic planning, operational efficiency programs, and capital market transactions.

Before joining ChromaDex, Gerber served in multiple leadership roles at Mattel, Inc. in Corporate Financial Planning and Investor Relations. Before joining Mattel, Gerber spent 11 years at the Capital Group Companies, one of the largest active asset managers in the world.

Gerber received her B.S. in Corporate Finance and Entrepreneurship from the University of Southern California. She is a Chartered Financial Analyst and a member of the CFA Society of Los Angeles.

ChromaDex encourages everyone to subscribe to our alerts in anticipation of exciting upcoming news. To do so visit us at Alert Sign-Up.

ChromaDex Corp. is a global bioscience company dedicated to healthy aging.

ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside, commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio.